ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).

被引：3

作者：

Armstrong, Andrew J.

Szmulewitz, Russell Zelig

Petrylak, Daniel Peter

Holzbeierlein, Jeffrey M.

Villers, Arnauld

Azad, Arun

Alcaraz, Antonio

Alekseev, Boris Yakovlevich

Iguchi, Taro

Shore, Neal D.

Rosbrook, Brad

Baron, Benoit

Chen, Lucy F.

Stenzl, Arnulf

机构：

[1] Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA

[2] Univ Chicago, Chicago, IL 60637 USA

[3] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[4] Univ Kansas, Med Ctr, Westwood, KS USA

[5] Lille Univ, Univ Hosp Ctr, Dept Urol, Lille, France

[6] Monash Hlth, Melbourne, Vic, Australia

[7] Hosp Clin Barcelona, Dept Urol, Barcelona, Spain

[8] Hertzen Moscow Canc Res Inst, Moscow, Russia

[9] Osaka City Univ, Dept Urol, Grad Sch Med, Osaka, Japan

[10] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[11] Pfizer Inc, San Diego, CA USA

[12] Astellas Pharma Inc, Leiden, Netherlands

[13] Astellas Pharma Inc, Northbrook, IL USA

[14] Eberhard Karls Univ Tubingen, Univ Hosp, Dept Urol, Tubingen, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.5048

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5048

引用

页数：2

共 50 条

[1] Phase 3 Study of Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) or Placebo (PBO) in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): The Arches Trial
Horvath, Lisa
Armstrong, Andrew J.
Szmulewitz, Russell
Petrylak, Daniel
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Sugg, Jennifer
Baron, Benoit
Chen, Lucy
Stenzl, Arnulf
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 32 - 33
[2] Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
Armstrong, Andrew J.
Szmulewitz, Russell Zelig
Petrylak, Daniel Peter
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris Y.
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Sugg, Jennifer
Baron, Benoit
Chen, Lucy F.
Stenzl, Arnulf
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[3] Post hoc analysis of East Asian subpopulation in arches, a phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC)
Iguchi, Taro
Pu, Yeong-Shiau
Kimura, Go
Byun, Seok-Soo
Ha, Hong Koo
Hong, Jun Hyuk
Li, Jian-Ri
Sugg, Jennifer
Haas, Gabriel P.
Stenzl, Arnulf
Armstrong, Andrew J.
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 96 - 97
[4] ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
Alcaraz, A.
Szmulewitz, R. Z.
Shore, N.
Crawford, E. D.
Petrylak, D. P.
Holzbeierlein, J.
Villers, A.
Azad, A. A.
Alekseev, B.
Iguchi, T.
Gomez-Veiga, F.
Rosbrook, B.
Sugg, J.
Haas, G. P.
Stenzl, A.
Armstrong, A. J.
ANNALS OF ONCOLOGY, 2020, 31 : S523 - S524
[5] Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
Shore, Neal D.
Armstrong, Andrew J.
Szmulewitz, Russell Zelig
Petrylak, Daniel Peter
Holzbeierlein, Jeffrey
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris
Iguchi, Taro
Gomez-Veiga, Francisco
Rosbrook, Brad
Lee, Ho-Jin
Haas, Gabriel P.
Stenzl, Arnulf
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Stenzl, A.
Szmulewitz, R. Z.
Petrylak, D. P.
Holzbeierlein, J.
Villers, A.
Azad, A. A.
Alcaraz, A.
Alekseev, B. Y.
Iguchi, T.
Shore, N. D.
Rosbrook, B.
Baron, B.
Haas, G. P.
Morlock, R.
Ramaswamy, K.
Armstrong, A. J.
ANNALS OF ONCOLOGY, 2019, 30 : 332 - +
[7] Arches - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): post hoc analyses of high and low disease volume and risk groups
Hong, Jun Hyuk
Stenzl, Arnulf
Szmulewitz, Russell Z.
Petrylak, Daniel
Holzbeierlein, Jeffrey
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris Y.
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Baron, Benoit
Haas, Gabriel P.
Morlock, Robert
Ramaswamy, Krishnan
Armstrong, Andrew J.
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 102 - 103
[8] Androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: ARCHES
von Bueren, Moritz
Armstrong, Andrew J.
Szmulewitz, Russell
Petrylak, Daniel
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Sugg, Jennifer
Baron, Benoit
Chen, Lucy
Stenzl, Arnulf
SWISS MEDICAL WEEKLY, 2019, 149 : 16S - 16S
[9] China ARCHES: A multicenter phase III randomized doubleblind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) vs PBO plus ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Zhou, F.
Gongqian, Z.
Guo, H.
Hu, Z.
Zhang, X.
He, D.
He, Z.
Zhang, D.
Li, Y.
Kadeerbai, H.
Liu, Y.
Ye, D.
ANNALS OF ONCOLOGY, 2023, 34 : S971 - S971
[10] Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.
Azad, Arun
Iguchi, Taro
Alekseev, Boris
Shore, Neal D.
Sugg, Jennifer
Haas, Gabriel P.
Wozniak, Michele
O'Brien, Thomas
Laird, Douglas
Stenzl, Arnulf
Armstrong, Andrew J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →